AzTrials
AzTrials

Locally Advanced Oesophageal CancerAMCORNCT06597240

Home Monitoring During Chemoradiation

An observational study of Locally Advanced Oesophageal Cancer, run by University Medical Center Groningen at 1 site in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Chemoradiotherapy is part of standard treatment for patients with locally advanced oesophageal cancer. Some patients with oesophageal cancer treated with chemoradiotherapy do not complete treatment due to toxicity, or face complications after treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Locally Advanced Oesophageal Cancer
What is being tested?
AMCOR
Type of treatment
Medical device
How many people
30 participants
Where
1 siteNetherlands
Study dates
15 May 2025to Oct 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with head and neck carcinoma eligible for chemoradiation with a curative intent, and chemotherapy that consists of cisplatin will be included in this study.

Who may be able to join

  • Age ≥ 18 at the time of signing informed consent.
  • Histologically proven adenocarcinoma, squamous cell carcinoma or mixed type of the oesophagus or gastro-oesophageal junction.
  • Indication for definitive or neoadjuvant CRT, with chemotherapy that consists of weekly carboplatin/paclitaxel.
  • Written, informed consent.
  • Ability to comply with all protocol required actions (at home measurements are done individually by the participant him- or herself).

Who cannot join

  • Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent or the carrying out of the measurements at home.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Rudolf S.N. Fehrmann, MD, PhD contact

+31503611419

r.s.n.fehrmann@umcg.nl

Sjoukje F. Oosting, MD, PhD contact

+31503613411

s.oosting@umcg.nl

Netherlands1 site, 1 recruiting
  • University Medical Center Groningen

    Groningen, 9713 GZ

    Rudolf SN Fehrmann, MD, PhD, +31 50 361 1419, r.s.n.fehrmann@umcg.nl

    Sjoukje F. Oosting, MD, PhD, +31 50 361 3411, s.oosting@umcg.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: At-home Monitoring of Patients During Chemoradiation for Oesophageal CanceR: the AMCOR Trial

Chemoradiotherapy is part of standard treatment for patients with locally advanced oesophageal cancer. Some patients with oesophageal cancer treated with chemoradiotherapy do not complete treatment due to toxicity, or face complications after treatment. Therefore, there is a need for better tools for assessing patients' fitness for chemoradiotherapy and to pick up early signals of deteriorating overall physical condition and complications during and after treatment to timely implement supportive care measures. Tools enabling monitoring physical activity, vital parameters and creatinine concentration in the blood at home are available but have not yet been implemented in patients undergoing chemoradiotherapy for oesophageal cancer. The feasibility and added value remain unknown.

Read the detailed description

This is an observational feasibility study in which 30 ambulant patients with oesophageal cancer are continuously monitored from 1 week before chemoradiation until 3 weeks after chemoradiation for oesophageal cancer in addition to standard care.

We provide them with a monitoring kit of Siemens and a finger prick test of Nova Biomedical.

The monitoring kit of Siemens Healthineers contains multiple measuring tools, including:

  • a blood pressure measuring device, which will be applied to the upper arm.
  • an oxygen saturation measuring device, which will also measure the pulse when applied to the fingertip.
  • a scale which will measure body weight.
  • a skin thermometer which will detect body temperature.
  • An activity tracker/watch which will measure every step taken during the day when worn around the wrist by the participant. All measurements will be automatically send to the online portal, which can be seen by the investigators.

Participants will receive a dedicated smartphone with an application to monitor their measurements at home for the duration of their study participation. The telephone does not provide any other functions than the specific app function.

With a finger stick test participants will measure the creatinine level in the blood. Nova Max Pro™ Creat Meter is a handheld analyser and miniaturized, single-use biosensor for whole blood creatinine testing. It enables assessment of renal function by fingerstick capillary blood sampling at home. It uses 1.2 μL capillary blood and shows the result in 30 seconds on the screen in μmol/L. The patient will carry out this measurement once a week the day before routine blood testing in the hospital. The values are transferred to the app via a Bluetooth® connection.

We will collect information on quality of life (QoL) and taste before, during and after treatment using a Quality of Life Questionnaire (QLQ) and a taste questionnaire. For QoL we will use the validated questionnaires of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, the core instrument that consists of 30 questions and the QLQ-OES18, the oesophageal cancer module that consists of 18 questions. The QLQ-OES18 consists of four scales, i.e., dysphagia, eating, reflux and pain and six single items, being swallowing saliva, choking when swallowing, dry mouth, taste problems, coughing and speech problems. The QLQ-C30 questionnaire consists 30 items and questions the overall global health status/QoL score, with the use of five functioning scores (physical, role, emotional, cognitive, and social functioning) and three composite symptom scores (fatigue, nausea, and vomiting). Six single-symptom items are also assessed being pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea. The overall global health status and overall QoL score uses a seven-point Likert scale ranging from 'very poor' to 'excellent', and the remaining items in the EORTC use a four-point Likert scale ranging from 'not at all' to 'very much'. These scale scores are linearly converted to a 0-100 scale, where higher scores of the functioning scores and global QoL reflect higher levels of functioning and for the symptom scales higher scores reflect higher levels of symptom burden. Patients who reported 'a little' change for better or worse on a particular scale (function or symptom) had QLQ-C30 changes about 5 to 10. Those reporting 'moderate' change had changed about 10 to 20, and 'very much' change corresponded to a change greater than 20. A difference of 10 points up or down is often chosen as a clinically significant difference.

Taste will be assessed with the 'Chemotherapy-induced Taste Alteration Scale (CiTAS)'. This validated questionnaire consists of 18 questions with a Likert scale '1' to '5' (where '1' = no difficulty or absence of the disturbance and '5' = maximum difficulty or disturbance). It was developed based on semi-structured interviews with eight patients with cancer undergoing chemotherapy and is the first validated questionnaire regarding taste changes, available in many languages. It evaluates four dimensions of taste alterations: intensity of taste, discomfort, phantogeusie and parageusia, and general alterations of taste. The final score can be calculated by dividing the total score by the number of questions per section or in total, which gives an aim of the severity of the taste changes.

Being tested
AMCOR
Keywords
at-home monitoring, chemoradiation, oesophageal cancer
Medical subject headings
Esophageal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AMCORDevice

    Participants will collect biometric and quality of life data for 9 or 10 weeks at home, depending on treatment schedule. Continuous step counting will be used to register physical activity. Participants will be asked to measure their blood pressure, heart rate, oxygen saturation level, pain level and temperature each morning, and weight 3 times a week. These measurements consume little time and are not harmful. Once a week they will perform a finger stick test themselves to determine creatinine concentration in the blood. In addition, patients fill in three questionnaires at four time points which will take approximately 20 minutes to complete per time point. We do not foresee reasonable risks of these diagnostic procedures for the participants.

Study groups in NCT06597240
Study groupRoleWhat they receive
AMCORPatients >18 years with locally advanced oesophageal cancer requiring chemoradiotherapy with curative intent.
Receives: Device: AMCOR

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determine the feasibility of at home monitoring in addition to standard of care

    To determine the feasibility of at home monitoring in addition to standard care of patients with oesophageal cancer during chemoradiotherapy. Feasible is defined as ≥80% of measurements completed in ≥80% of the patients.

    Measured: From one week before the start of treatment until three weeks after the end of treatment

Secondary outcomes (7)
  1. Determine completion rates

    Determine completion rates per type of measurement

    Measured: From one week before the start of treatment until three weeks after the end of treatment

  2. Determine the number of extra hospital visits

    Determine the number of extra hospital visits triggered by home measurements.

    Measured: From one week before the start of treatment until three weeks after the end of treatment

  3. Determine the number of extra telephone contacts

    Determine the number of extra telephone contacts triggered by home measurements, subdivided by patient-initiated and nurse-initiated calls

    Measured: From one week before the start of treatment until three weeks after the end of treatment

  4. Determine radiotherapy and chemotherapy completion rates

    Determine radiotherapy and chemotherapy completion rates

    Measured: From one week before the start of treatment until three weeks after the end of treatment

  5. Assess changes in quality of life from baseline in the domains overall health/QoL score, dysphagia and fatigue of the validated EORTC QLQ-C30 and QLQ-OES18.

    The QLQ-OES18 consists of four scales, i.e., dysphagia, eating, reflux and pain and six single items, being swallowing saliva, choking when swallowing, dry mouth, taste problems, coughing and speech problems. The QLQ-C30 consists 30 items and questions the global health status/QoL, with the use of five functioning scores (physical, role, emotional, cognitive, and social functioning) and three symptom scores (fatigue, nausea, and vomiting). Six single-symptom items are also assessed being pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea. The global health status and QoL score uses a seven-point Likert scale ranging from 'very poor' to 'excellent', and the remaining items in the EORTC use a four-point Likert scale ranging from not at all to very much. These scores are linearly converted to a 0-100 scale, where higher scores of the functioning scores and global QoL reflect higher levels of functioning and for the symptom scores reflect higher levels of symptom burden.

    Measured: From one week before the start of treatment until three weeks after the end of treatment

  6. Assess taste changes from baseline with the use of Chemotherapy-induced Taste Alteration Scale (CiTAS) questionnaire

    Assess taste changes from baseline with the Chemotherapy-induced Taste Alteration Scale (CiTAS), which consists of 18 questions with a Likert scale of 1 to 5 (where 1 = no difficulty or absence of the disturbance and 5 = maximum difficulty or disturbance). The final score can be calculated by dividing the total score by the number of questions per section or in total, which gives an aim of the severity of the taste changes.

    Measured: From one week before the start of treatment until three weeks after the end of treatment

  7. Assess changes in quality of life from baseline in the remaining symptoms and domains of the EORTC QLQ-C30 and the oesophageal cancer specific EORTC QLQ-OES18.

    The QLQ-OES18 consists of four scales, i.e., dysphagia, eating, reflux and pain and six single items, being swallowing saliva, choking when swallowing, dry mouth, taste problems, coughing and speech problems. The QLQ-C30 consists 30 items and questions the global health status/QoL, with the use of five functioning scores (physical, role, emotional, cognitive, and social functioning) and three symptom scores (fatigue, nausea, and vomiting). Six single-symptom items are also assessed being pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea. The global health status and QoL score uses a seven-point Likert scale ranging from 'very poor' to 'excellent', and the remaining items in the EORTC use a four-point Likert scale ranging from not at all to very much. These scores are linearly converted to a 0-100 scale, where higher scores of the functioning scores and global QoL reflect higher levels of functioning and for the symptom scores reflect higher levels of symptom burden.

    Measured: From one week before the start of treatment until three weeks after the end of treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2024
  2. Study start15 May 2025
  3. Primary completionOct 2026 (estimated)
  4. Study completionOct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06597240
Sponsor's protocol ID
PaNaMa nr. 11386
Acronym
AMCOR
Status last verified
Jun 2025
First submitted
17 Jan 2023
Last updated
14 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Locally Advanced Oesophageal Cancer, run by University Medical Center Groningen at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Rudolf S.N. Fehrmann, MD, PhD (+31503611419, r.s.n.fehrmann@umcg.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determine the feasibility of at home monitoring in addition to standard of care (time frame: From one week before the start of treatment until three weeks after the end of treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in